Dr Reddy's to market Cosmederm's skincare range in India
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratorieshas entered a licensing and distribution agreement with Cosmederm Technologies, under which Dr Reddy's has exclusive rights to distribute Cosmederm's skincare range in India. The partnership covers two product lines – Refinity peel kits (glycolic acid 70%) and Cosmederm peel kits (glycolic acid 50%). Cosmederm offers potent, non-irritating skincare products in areas such as anti-ageing, acne, pruritis and rosacea. The alliance gives Dr Reddy's an entry to the aesthetic dermatology segment in India and consolidates its position in cosmeceuticals. The Indian market for aesthetic dermatology is estimated at about Rs1 billion ($22.5 million) and growing at more than 50% annually.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.